2-amino-1-benzyl-4,5,6,7-tetrahydro-1H-indole-3-carbonitrile | 61479-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-amino-1-benzyl-4,5,6,7-tetrahydro-1H-indole-3-carbonitrile
• 英文别名: 2-amino-1-benzyl-4,5,6,7-tetrahydroindole-3-carbonitrile
• CAS: 61479-14-9
• 化学式: C₁₆H₁₇N₃
• 分子量: 251.331
• InChiKey: XKKFLDQPHGDREE-UHFFFAOYSA-N

物化性质

• 沸点：
  484.6±45.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  54.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-amino-1-benzyl-4,5,6,7-tetrahydro-1H-indole-3-carbonitrile 在 三氯化铝 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 9.5h， 生成 4-氯-6,7,8,9-四氢-5H-嘧啶并[4,5-B]吲哚
  参考文献：
  名称：

  4-(Phenylamino)pyrrolopyrimidines:  Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase

  摘要：

  Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGF-R protein tyro sine kinase (PTK), 4(phenylamino)-7H-pyrrolo[2,3-d]pyrimidines have been identified as a novel class of potent EGF-R protein tyrosine kinase inhibitors. In an interactive process, this class of compounds was then optimized. 13, 14, 28, 36, 37, and 44, the most potent compounds of this series, inhibited the EGF-R PTK with IC50 values in the low nanomolar range. High selectivity toward a panel of nonreceptor tyrosine kinases (c-Src, v-Abl) and serine/threonine kinases (PKC alpha, PKA) was observed. Kinetic analysis revealed competitive type kinetics relative to ATP. In cells, EGF-stimulated cellular tyrosine phosphorylation was inhibited by compounds 13, 36, 37, and 44 at IC50 values between 0.1 and 0.4 mu M, whereas PDGF-induced tyrosine phosphorylation was not affected by concentrations up to 10 M. In addition, these compounds were able to selectively inhibit c-fos mRNA expression in EGF-dependent cell lines with IC50 values between 0.1 and 2 mu M, but did not affect c-fos mRNA induction in response to PDGF or PMA (IC50 > 100 mu M) Proliferation of the EGF-dependent MK cell line was inhibited with similar IC50 values. From SAR studies, a binding mode for 4-(phenylamino)-7H-pyrrolo [2,3-d]pyrimidines as well as for the structurally related 4-(phenylamino)quinazolines at the ATP-binding site of the EGF-R tyrosine kinase is proposed. 4-(Phenylamino)-7H-pyrrolo [2,3-d]pyrimidines therefore represent a new class of highly potent tyrosine kinase inhibitors which preferentially inhibit the EGF-mediated signal transduction pathway and, ha ire the potential for further evaluation as anticancer agents.

  DOI：

  10.1021/jm960118j

文献信息

• Synthesen bicyclischer 1,2,6-Thiadiazine
  作者：Wolfgang Offermann、Kurt Eger、Hermann J. Roth

  DOI：10.1002/ardp.19813140213

  日期：——

  α‐Aminosäureamide aus der Pyrrol‐ Furan‐ und Thiophen‐Reihe werden zu neuen Schwefelheterocyclen umgesetzt. Die Stabilität dieser Verbindungen wird untersucht.

  来自吡咯、呋喃和噻吩系列的α-氨基酸酰胺转化为新的硫杂环。正在研究这些化合物的稳定性。
• [EN] PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF<br/>[FR] PYRROLOPYRIMIDINES ET LEURS PROCEDES DE PREPARATION
  申请人：NOVARTIS AG

  公开号：WO1997002266A1

  公开（公告）日：1997-01-23

  (EN) Described are 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula (I) wherein the symbols are as defined in claim 1. Those compounds inhibit tyrosine protein kinase and can be used in the treatment of hyperproliferative diseases, for example tumour diseases.(FR) L'invention a pour objet des dérivés de 7H-pyrrolo(2,3-d)pyrimidine de formule (I) dans laquelle les symboles sont ceux définis dans la revendication 1. Ces composés inhibent la tyrosine protéine kinase et sont utiles pour traiter les maladies hyperprolifératives, par exemple, les maladies tumorales.

  (中文) 描述了公式（I）中符号如权利要求1所定义的7H-吡咯并[2,3-d]嘧啶衍生物。这些化合物抑制酪氨酸蛋白激酶，并可用于治疗增生性疾病，例如肿瘤疾病。
• 9H-pyrido[2,B-8]indole-3-carboxylic acid ester compounds having useful
  申请人：Beecham Group p.l.c.

  公开号：US04952584A1

  公开（公告）日：1990-08-28

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-4 alkyl wherein the phenyl moiety is optionally substituted by one or more C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl, cyano, carbamoyl or carboxy groups; R.sub.2, R.sub.3 and R.sub.4 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, chloro, fluoro, trifluoromethyl, nitro, amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl, cyano, carbamoyl and carboxy, and phenyl, phenyl C.sub.1-4 alkyl or phenyl C.sub.1-4 alkoxy in which any phenyl moiety is optionally substituted by any of these groups; R.sub.5 and R.sub.6 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.1-7 alkanoyl, C.sub.1-6 alkylsulphonyl, di-(C.sub.1-6 alkyl)amino C.sub.1-6 alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C.sub.1-4 alkyl, benzoyl, phenyl C.sub.2-7 alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3, amino or carboxy, or R.sub.5 and R.sub.6 together are C.sub.2-6 polymethylene optionally interrupted by oxygen or NR.sub.9 wherein R.sub.9 is hydrogen or C.sub.1-6 alkyl optionally substituted by hydroxy; R.sub.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-4 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; and --CO.sub.2 R.sub.8 is a pharmaceutically acceptable ester group, processes for its preparation and its use for the treatment or prophylaxis of anxiety or depression.

  化合物式（I）或其药学上可接受的盐：##STR1## 其中：R.sub.1是氢、C.sub.1-6烷基、苯基或苯基C.sub.1-4烷基，其中苯基部分可选择性地被一个或多个C.sub.1-6烷基、C.sub.1-6烷氧基、C.sub.1-6烷基硫基、羟基、C.sub.2-7烷酰基、卤、三氟甲基、硝基、氨基（可选择性地被一个或两个C.sub.1-6烷基或C.sub.2-7烷酰基取代）、氰基、氨基甲酰基或羧基取代；R.sub.2、R.sub.3和R.sub.4独立选择自氢、C.sub.1-6烷基、C.sub.1-6烷氧基、C.sub.1-6烷氧羰基、C.sub.1-6烷基硫基、羟基、C.sub.2-7烷酰基、氯、氟、三氟甲基、硝基、氨基（可选择性地被一个或两个C.sub.1-6烷基或C.sub.2-7烷酰基取代）、氰基、氨基甲酰基和羧基、苯基、苯基C.sub.1-4烷基或苯基C.sub.1-4烷氧基，其中任何苯基部分可选择性地被任何这些基团之一取代；R.sub.5和R.sub.6独立选择自氢、C.sub.1-6烷基、C.sub.3-7环烷基、C.sub.3-7环烷基-C.sub.1-4烷基、C.sub.2-6烯基、C.sub.1-7烷酰基、C.sub.1-6烷基磺酰基、二-(C.sub.1-6烷基)氨基C.sub.1-6烷基、3-氧代丁基、3-羟基丁基、苯基、苯基C.sub.1-4烷基、苯甲酰基、苯基C.sub.2-7烷酰基或苯磺酰基，其中任何苯基部分可选择性地被一个或两个卤、C.sub.1-6烷基、C.sub.1-6烷氧基、CF.sub.3、氨基或羧基取代，或R.sub.5和R.sub.6一起是C.sub.2-6聚亚甲基，可选择性地被氧或NR.sub.9中断，其中R.sub.9是氢或C.sub.1-6烷基，可选择性地被羟基取代；R.sub.7是氢、C.sub.1-6烷基、C.sub.3-6环烷基、C.sub.3-6环烷基-C.sub.1-4烷基、C.sub.2-6烯基或C.sub.2-6炔基；和--CO.sub.2R.sub.8是药学上可接受的酯基，其制备方法及其用于治疗或预防焦虑或抑郁症的用途。
• Pyrido[2,3-b]indoles
  申请人：BEECHAM GROUP PLC

  公开号：EP0249301A1

  公开（公告）日：1987-12-16

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R, is hydrogen, C1-6 alkyl, phenyl or phenyl C1-4 alkyl wherein the phenyl moiety is optionally substituted by one or more C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, hydroxy, C2-7 alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C1-6 alkyl groups or by C2-7 alkanoyl, cyano, carbamoyl or carboxy groups; R2, R3 and R4 are independently selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkylthio, hydroxy, C2-7 alkanoyl, chloro, fluoro, trifluoromethyl, nitro, amino optionally substituted by one or two C1-6 alkyl groups or by C2-7 alkanoyl, cyano, carbamoyl and carboxy, and phenyl, phenyl C1-4 alkyl or phenyl C1-4, alkoxy in which any phenyl moiety is optionally substituted by any of these groups; R5 and R6 are independently selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-6 alkenyl, C1-7 alkanoyl, C1-6 alkylsulphonyl, di-(C1-6 alkyl)amino C1-6 alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C1-4 alkyl, benzoyl, phenyl C2-7 alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C1-6 alkyl, C1-8 alkoxy, CF3, amino or carboxy, or R6 and R6 together are C2-6 polymethylene optionally interrupted by oxygen or NR9 wherein R9 is hydrogen or C1-6 alkyl optionally substituted by hydroxy; R7 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl, C2-6 alkenyl or C2-6 alkynyl; and -CO2R8 is a pharamaceutically acceptable ester group, processes for its preparation and its use as a pharmaceutical.

  式 (I) 的化合物或其药学上可接受的盐： 其中 R，是氢、C1-6 烷基、苯基或苯基 C1-4 烷基，其中苯基任选被一个或多个 C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、羟基、C2-7 烷酰基、卤代、三氟甲基、硝基、任选被一个或两个 C1-6 烷基或 C2-7 烷酰基取代的氨基、氰基、氨基甲酰基或羧基取代； R2、R3 和 R4 独立选自氢、C1-6 烷基、C1-6 烷氧基、C1-6 烷氧羰基、C1-6 硫代烷基、羟基、C2-7 烷酰基、氯、氟、三氟甲基、硝基、任选被一个或两个 C1-6 烷基或 C2-7 烷酰基、氰基、氨基甲酰基和羧基取代的氨基，以及苯基、苯基 C1-4 烷基或苯基 C1-4 烷氧基，其中任何苯基分子任选被上述任一基团取代； 苯基、苯基 C1-4 烷基、苯甲酰基、苯基 C2-7 烷酰基或苯磺酰基，其中任何苯基可选择被一个或两个卤素、C1-6 烷基、C1-8 烷氧基、CF3、氨基或羧基取代，或 R6 和 R6 合在一起是可选择被氧或 NR9 中断的 C2-6 聚亚甲基，其中 R9 是氢或可选择被羟基取代的 C1-6 烷基； R7是氢、C1-6烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C2-6烯基或C2-6炔基；和 -CO2R8是法学上可接受的酯基，其制备工艺和作为药物的用途。
• Synthesis and cytotoxic activity of 5,6-heteroaromatically annulated pyridine-2,4-diamines
  作者：C. Willemann、R. Grünert、P.J. Bednarski、R. Troschütz

  DOI：10.1016/j.bmc.2009.05.016

  日期：2009.7

  A series of 5,6-heteroaromatically annulated pyridine-2,4-diamines have been synthesized and their in vitro cytotoxic activities evaluated against six human cancer cell lines. Benzo[g] annulated pyrido[2,3-b]indolediamines 7a-b and 8 showed relatively high cytotoxic activity as well as most of the diamines with pyrrolo[2,3-b] pyridine 17, thieno[2,3-b] pyridine and furo[2,3-b] pyridine 26-28, 1,8-naphthyridine 32 and 34 and benzo[h] quinoline 37 skeletons. Surprisingly, pyrido[2,3-b] indolediamines 13 and 14 without benzo[g] annulation were inactive. None of the new compounds were as potent as ellipticine, the reference compound. (C) 2009 Elsevier Ltd. All rights reserved.